Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Multicenter, Randomized, Controlled Clinical Trial of the Safety and Efficacy of Azvudine vs. Nirmatrelvir-Ritonavir in Hospitalized Patients With Moderate to Severe COVID-19 Infection

NCT05697055 is registered in ClinicalTrials.gov with Shandong Provincial Hospital as lead sponsor.

NCT NCT05697055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05697055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Multicenter, Randomized, Controlled Clinical Trial of the Safety and Efficacy of Azvudine vs. Nirmatrelvir-Ritonavir in Hospitalized Patients With Moderate to Severe COVID-19 Infection
Lead sponsor
Shandong Provincial Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
January 21, 2023
Completion date
July 21, 2023
Enrollment
410 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19